Study of vedolizumab for ulcerative colitis or Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have moderate to severely active ulcerative colitis or Crohn's disease.
- You have tried at least one previous treatment (like steroids, immunomodulators, or advanced therapy) that didn't work or caused side effects.
- You have not previously taken vedolizumab or similar drugs (like natalizumab or efalizumab).
- You have not failed more than 2 advanced treatments in the past.
- You have no active infections, unstable medical conditions, or major neurological disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
This study tests whether adding a special probiotic (VSL#3) to vedolizumab helps people with moderate ulcerative colitis more than vedolizumab alone. You may qualify if you are already planning to start vedolizumab and haven't responded well enough to other treatments.
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.